DRESDEN, Germany, May. 04, 2022 — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a novel microcarrier for increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The product, termed beadMATRIX, is designed to enable MSC proliferation and harvest in xeno-/serum-free media with high efficiency and stemness.
High quantities of cells are needed to facilitate the establishment of MSC-based therapies, especially allogeneic MSC therapies. More than 10 billion MSCs are necessary for clinical trials, and more than 100 billion MSCs for commercialized therapies. Thus, MSC manufacturing is dependent on high-level expansion, necessitating microcarrier/bioreactor-based cell culture.
The rise in FDA approvals of MSC therapies and more than 100 clinical trials running yearly, has led to an unprecedented rate of innovation in supporting areas, including cell media and reactor design. However, microcarrier technologies have remained largely unchanged with few suppliers offering this resource. To support the rate of development in cell manufacturing, and increase access to microcarriers which enable mass production of MSCs, beadMATRIX has been launched to the market.
‘‘Cell performance on beadMATRIX is class-leading, and we provide documentation to enable the implementation of our products in our customer’s workflows’’ says Dr. Kristina Thamm, Head of Project Services at denovoMATRIX. ‘‘The beadMATRIX launch rounds out our MSC ecosystem of products, which allows the seamless transition from MSC isolation, through seed train expansion in 2D to the 3D scale-up’’ continues Dr. Dejan Hušman, CEO of denovoMATRIX. This new launch will aid companies in MSC therapy to transition into 3D scale-up, and usher in the next generation of approved treatments for patients.
Detailed information on beadMATRIX is available here.
About denovoMATRIX GmbH
denovoMATRIX deploys a modular, biomimetic coating technology to enable high performance cell culture, bringing cell therapies to patients and accelerating the path to market for clean meat. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell-based therapy and clean meat companies with solutions, denovoMATRIX is at the forefront of innovation in cell manufacturing processes.
For more information, visit: https://www.denovomatrix.com/beadmatrix/